Institutional Investor’s Pro-Mimedx Group Inc (NASDAQ:MDXG) Sentiment In Q3 2017

January 21, 2018 - By Clifton Ray

 Institutional Investor's Pro Mimedx Group Inc (NASDAQ:MDXG) Sentiment In  Q3 2017

Sentiment for Mimedx Group Inc (NASDAQ:MDXG)

Mimedx Group Inc (NASDAQ:MDXG) institutional sentiment decreased to 1.97 in Q3 2017. Its down -0.05, from 2.02 in 2017Q2. The ratio has dropped, as 128 institutional investors increased or opened new positions, while 65 reduced and sold their stock positions in Mimedx Group Inc. The institutional investors in our partner’s database reported: 77.22 million shares, up from 66.99 million shares in 2017Q2. Also, the number of institutional investors holding Mimedx Group Inc in their top 10 positions decreased from 3 to 2 for a decrease of 1. Sold All: 21 Reduced: 44 Increased: 80 New Position: 48.

MiMedx Group, Inc., a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. The company has market cap of $1.58 billion. It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts. It has a 45.69 P/E ratio. The companyÂ’s proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization.

The stock decreased 0.42% or $0.06 during the last trading session, reaching $14.21. About 1.31 million shares traded. MiMedx Group, Inc. (NASDAQ:MDXG) has risen 107.87% since January 21, 2017 and is uptrending. It has outperformed by 91.17% the S&P500.

Analysts await MiMedx Group, Inc. (NASDAQ:MDXG) to report earnings on February, 22. They expect $0.11 EPS, up 120.00 % or $0.06 from last year’s $0.05 per share. MDXG’s profit will be $12.22M for 32.30 P/E if the $0.11 EPS becomes a reality. After $0.05 actual EPS reported by MiMedx Group, Inc. for the previous quarter, Wall Street now forecasts 120.00 % EPS growth.

Kestrel Investment Management Corp holds 2.86% of its portfolio in MiMedx Group, Inc. for 681,000 shares. Tiedemann Wealth Management Llc owns 1.57 million shares or 2.2% of their US portfolio. Moreover, Millrace Asset Group Inc. has 1.29% invested in the company for 115,835 shares. The Georgia-based Rowland & Co Investment Counsel Adv has invested 1.29% in the stock. Wildcat Capital Management Llc, a Texas-based fund reported 500,000 shares.#img1#

MiMedx Group, Inc. (NASDAQ:MDXG) Ratings Coverage

Ratings analysis reveals 75% of MiMedx Group’s analysts are positive. Out of 8 Wall Street analysts rating MiMedx Group, 6 give it “Buy”, 2 “Sell” rating, while 0 recommend “Hold”. The lowest target is $9 while the high is $21.0. The stock’s average target of $14.71 is 3.52% above today’s ($14.21) share price. MDXG was included in 27 notes of analysts from July 29, 2015. The stock of MiMedx Group, Inc. (NASDAQ:MDXG) earned “Buy” rating by Needham on Wednesday, October 14. As per Tuesday, November 14, the company rating was maintained by Needham. On Wednesday, August 30 the stock rating was maintained by Needham with “Buy”. The rating was downgraded by Needham to “Buy” on Wednesday, July 29. The firm has “Buy” rating given on Monday, June 26 by Needham. The firm earned “Sell” rating on Monday, December 12 by UBS. The firm has “Overweight” rating given on Wednesday, January 20 by First Analysis. The rating was maintained by Piper Jaffray with “Buy” on Thursday, September 21. The company was downgraded on Tuesday, May 23 by First Analysis. Needham maintained MiMedx Group, Inc. (NASDAQ:MDXG) rating on Thursday, January 18. Needham has “Buy” rating and $21.0 target.

More notable recent MiMedx Group, Inc. (NASDAQ:MDXG) news were published by: Prnewswire.com which released: “MiMedx Announces First Patients Have Been Enrolled In The Phase 3 Clinical …” on January 16, 2018, also Seekingalpha.com with their article: “MiMedx down 5% on new Viceroy report of misconduct” published on November 21, 2017, Streetinsider.com published: “MiMedx Group (MDXG) Reports First Patient Enrollment in Phase 3 Clinical Trial …” on January 17, 2018. More interesting news about MiMedx Group, Inc. (NASDAQ:MDXG) were released by: Seekingalpha.com and their article: “MiMedx: Unique Opportunity Provided By Aggressive Shorts” published on January 02, 2018 as well as Streetinsider.com‘s news article titled: “MiMedx Group (MDXG) Provides Commentary on Magistrate Recommendation in …” with publication date: January 18, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: